Five-year relapse-free survival was noninferior with 3 versus 6 months of capecitabine and oxaliplatin.
Severity of neutropenia and concurrent presence of other cytopenias increase the likelihood of a viral infection or hematological malignancy.
Progression-free survival remained improved versus docetaxel alone during extended follow-up.
Rates of hypophosphatemia were higher with ferric carboxymaltose than with ferric derisomaltose.
Highlights of the latest gastrointestinal cancer trials
A new guideline standardizes best diagnostic practices.
Older patients represent a large majority of newly diagnosed cases and have high risk for early death.
Early mortality was elevated in men with preexisting cardiovascular disease after receiving abiraterone acetate or enzalutamide therapy.
VTE recurrence increased with the number of metabolic syndrome components.
Risks for CRC incidence and death are higher in UC patients than in population-based controls but may be on the decline.
Metastasis-free survival was significantly longer with apalutamide than with placebo.
Contrary to prior findings, adding olaparib to paclitaxel failed to improve survival in patients with disease progression following chemotherapy.
Assessment of tumor mutation burden using targeted next-generation sequencing may be predictive of benefit from PD-1 and PD-L1 inhibitors.
Outcomes were not superior with 5 versus 2.5 years of extended letrozole therapy.
Overall survival was significantly shorter among MGUS patients than among a matched control population in a long-term follow-up study.
Survival is similar between BRCA mutation carriers versus those with sporadic disease.
Adding tumor-treating electrical-field therapy to maintenance temozolomide chemotherapy significantly improved survival in patients with newly diagnosed glioblastoma.
Overall survival was not improved with the PD-L1 inhibitor atezolizumab versus chemotherapy in patients with highest PD-L1 expression.
First-line therapy demonstrated antitumor activity in a phase II study.
Disease-free survival is significantly improved in patients who restart therapy versus those who do not restart after discontinuation.